CBD and sleep: what science really says in 2026

According to the Institut national du sommeil et de la vigilance, one adult in three reports sleep problems at least three times a week, and the average sleep duration of the French now sits below the recommended seven-hour threshold. The HAS updated its recommendations on chronic insomnia in 2024: cognitive behavioural therapy is positioned there as first line, ahead of hypnotics. There is no mention of CBD in them: this product is the subject of no official French recommendation for sleep disorders.

The scientific literature remains limited. The most cited study, Shannon et al., *The Permanente Journal*, 2019, followed 72 adults consulting for anxiety or sleep problems: after a month of CBD, 66.7 % reported a subjective improvement, but the authors themselves stress the absence of a placebo group and the self-reported nature of the measures. Other trials give heterogeneous results, some finding no distinction between CBD and a placebo. The EFSA, in its update of 9 February 2026, considers the toxicological and clinical data insufficient to authorise a specific claim.

Since the Conseil d'État decision of 29 December 2022 (no. 444887), the sale of hemp flowers and leaves at under 0.30 % THC in the finished product is legal in France. The MILDECA recalls that no therapeutic claim may accompany these products: any wording of the "against insomnia" type exposes the seller to reclassification as a medicine by presentation, penalised under article L.5111-1 of the Public Health Code.

The regulatory turning point of 2026 is the EFSA opinion published on 9 February: a provisionally safe daily dose of 0.0275 mg/kg of body weight per day, that is around 2 mg for a 70 kg adult. This dose applies to supplements of CBD purified to 98 %, without nanoparticles, and excludes the under-25s, pregnant women and people on medication. The great majority of CBD oils sold today exceed that threshold from the first recommended intake, which does not mean immediate danger, but does call for caution in regular use.

Before looking for a product, the INSV and the HAS recall the pillars of good sleep hygiene: regular bedtimes and waking times, exposure to morning light, no bright screens in the hour before bed, caffeine avoided after 2 p.m., a cool bedroom around 18-19 °C and regular physical activity outside the evening. These "non-medicinal" measures make up the first line of response recommended by the HAS; no product, CBD included, makes up for their absence. Our guide to CBD dosage details the usage markers for those who wish to build it into an evening ritual all the same.

CBD is not a medicine. In the event of sleep problems persisting for more than three weeks, consult a healthcare professional.

Is CBD a natural sleeping pill?

No. No French body (ANSM, HAS, ANSES) or European one (EFSA) recognises CBD as a sleeping pill. It is a well-being product with no recognised therapeutic purpose.

How long before an effect is felt?

Regular users describe perceiving an effect between 30 and 90 minutes after a sublingual intake. These durations remain self-reported averages, not validated pharmacological data.

Is CBD compatible with a prescribed sleeping pill?

It is essential to ask the prescribing doctor: CBD interacts with several liver enzymes (cytochrome P450) involved in metabolising many hypnotics and anxiolytics.

Can I drive the next morning after taking CBD?

Consuming CBD can lead to a positive saliva test for THC, even with a legal product. The Cour de cassation confirmed on 21 June 2023 that the legality of the product does not exonerate the driver.